Author:
Yang Ying,Wang Dong,Cui Lei,Ma Hong-Hao,Zhang Li,Lian Hong-Yun,Zhang Qing,Zhao Xiao-Xi,Zhang Li-Ping,Zhao Yun-Ze,Li Na,Wang Tian-You,Li Zhi-Gang,Zhang Rui
Abstract
Purpose We sought to investigate the effectiveness and safety of dabrafenib in children with <i>BRAF</i><sup>V600E</sup>-mutated Langerhans cell histiocytosis (LCH). Materials and Methods A retrospective analysis was performed on 20 children with <i>BRAF</i><sup>V600E</sup>-mutated LCH who were treated with dabrafenib. Results The median age at which the patients started taking dabrafenib was 2.3 years old (range, 0.6 to 6.5 years). The ratio of boys to girls was 2.3:1. The median follow-up time was 30.8 months (range, 18.9 to 43.6 months). There were 14 patients (70%) in the risk organ (RO)<sup>+</sup> group and six patients (30%) in the RO<sup>–</sup> group. All patients were initially treated with traditional chemotherapy and then shifted to targeted therapy due to poor control of LCH or intolerance to chemotherapy. The overall objective response rate and the overall disease control rate were 65% and 75%, respectively. During treatment, circulating levels of cell-free <i>BRAF</i><sup>V600E</sup> (cf<i>BRAF</i><sup>V600E</sup>) became negative in 60% of the patients within a median period of 3.0 months (range, 1.0 to 9.0 months). Grade 2 or 3 adverse effects occurred in five patients. Conclusion Some children with <i>BRAF</i><sup>V600E</sup>-mutated LCH may benefit from monotherapy with dabrafenib, especially high-risk patients with concomitant hemophagocytic lymphohistiocytosis and intolerance to chemotherapy. The safety of dabrafenib is notable. A prospective study with a larger sample size is required to determine the optimal dosage and treatment duration.
Funder
Capital’s Funds for Health Improvement and Research
The Pediatric Medical Coordinated Development Center of Beijing Hospitals Authority
National Natural Science Foundation of China
National Science and Technology Key Projects
Beihang University & Capital Medical University Advanced Innovation Center for Big Data-Based Precision Medicine Plan
Publisher
Korean Cancer Association
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献